News - AKT1 mutation - LARVOL VERI

10d

MK-7075 (Miransertib) in Proteus Syndrome (clinicaltrials.gov)

P2, N=45, Recruiting, National Human Genome Research Institute (NHGRI) | Trial completion date: Mar 2028 --> Jul 2028 | Trial primary completion date: Mar 2026 --> Jul 2026

10 days ago

Trial completion date • Trial primary completion date

AKT1 (V-akt murine thymoma viral oncogene homolog 1)

AKT1 mutation

miransertib (MK-7075)

12d

Clinicopathological spectrum of non-sinonasal intestinal-type adenocarcinomas of the head and neck: Systematic review of case reports, case series, and cross-sectional studies. (PubMed, Med Oral Patol Oral Cir Bucal)

Non-sinonasal ITACs are rare, aggressive malignancies requiring accurate diagnosis and further molecular investigation to improve management and outcomes.

12 days ago

Observational data • Journal

EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • MUC1 (Mucin 1) • KMT2C (Lysine Methyltransferase 2C) • CDX2 (Caudal Type Homeobox 2) • MUC5B (Mucin 5B, Oligomeric Mucus/Gel-Forming) • MUC5AC (Mucin 5AC)

TP53 mutation • EGFR mutation • AKT1 mutation • MLL mutation

16d

Network centric identification of PI3K/Akt hub proteins as key oncogenic drivers and therapeutic targets. (PubMed, Sci Rep)

Functional enrichment analysis highlights the therapeutic relevance of these hubs, while 5.8% of identified proteins are oncogenes, reinforcing their candidacy for therapies. This study provides a systematic, network-based framework for identifying and prioritizing hub proteins in the PI3K/Akt pathway, with potential implications for rational multi-target drug design in precision oncology.

16 days ago

Journal

EGFR (Epidermal growth factor receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)

EGFR mutation • PIK3CA mutation • AKT1 mutation

20d

Subglottic Laryngeal Salivary Gland Intraductal Papillary Mucinous Neoplasm with GNAS Mutation: A Case Report and Review of the Literature. (PubMed, Head Neck Pathol)

However, the classification of the neoplasm remains a controversial issue, with the WHO noting that it is still not established whether SG IPMN should be classified separately or within the mucinous adenocarcinoma spectrum as a potential precursor [2]. We describe an unusual case of a minor salivary gland papillary mucinous neoplasm presenting in a novel location (subglottic larynx) with a novel mutational driver for this entity (GNAS R844H mutation), and briefly review the literature surrounding SG IPMN, its classification and related tumours.

20 days ago

Journal

AKT1 (V-akt murine thymoma viral oncogene homolog 1) • GNAS (GNAS Complex Locus)

AKT1 mutation

28d

Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. (PubMed, Clin Cancer Res)

In ESR1-mutant MBC, elacestrant treatment durations support the routine use of elacestrant monotherapy in appropriately selected patients. For patients with concurrent ESR1 and PI3K-pathway mutations, single-agent activity was comparable to outcomes observed in phase III studies.

28 days ago

Journal

ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)

HR positive • PIK3CA mutation • PTEN mutation • ESR1 mutation • AKT1 mutation

fulvestrant • Orserdu (elacestrant)

Metastasizing Ameloblastoma Mimicking Squamous Cell Carcinoma of the Lung and Harboring an AKT1 Mutation. (PubMed, Head Neck Pathol)

Molecular analysis of the metastasis and original jaw lesion revealed a mutation of AKT1 (c.49G > A p.(Glu17Lys) COSMIC ID: COSM33765) but no mutations in the BRAF gene were identified. This case illustrates the critical necessity of a thorough clinical history of previous neoplasia, even many years following treatment, as well as the role of molecular profiling for identifying novel targeted treatment options.

1 month ago

Journal • IO biomarker

BRAF (B-raf proto-oncogene) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)

BRAF mutation • AKT1 mutation

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial (clinicaltrials.gov)

P2, N=33, Recruiting, National Cancer Institute (NCI) | Active, not recruiting --> Recruiting

1 month ago

Enrollment open

AKT2 (V-akt murine thymoma viral oncogene homolog 2)

AKT1 mutation

paclitaxel • ipatasertib (RG7440)

2ms

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (clinicaltrials.gov)

P=N/A, N=50000, Recruiting, Massive Bio, Inc. | Trial completion date: Jun 2027 --> Jun 2040 | Trial primary completion date: Dec 2026 --> Dec 2038

2 months ago

Trial completion date • Trial primary completion date

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • STK11 (Serine/threonine kinase 11) • NPM1 (Nucleophosmin 1) • HRAS (Harvey rat sarcoma viral oncogene homolog) • DNMT3A (DNA methyltransferase 1) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • RB1 (RB Transcriptional Corepressor 1) • CLDN18 (Claudin 18) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • NRG1 (Neuregulin 1) • POLE (DNA Polymerase Epsilon) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • PD-1 (Programmed cell death 1) • CCND1 (Cyclin D1) • MCL1 (Myeloid cell leukemia 1) • KDR (Kinase insert domain receptor) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • VEGFA (Vascular endothelial growth factor A) • BCL6 (B-cell CLL/lymphoma 6) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • PTCH1 (Patched 1) • FGFR4 (Fibroblast growth factor receptor 4) • MSH6 (MutS homolog 6) • CDK4 (Cyclin-dependent kinase 4) • MSH2 (MutS Homolog 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MAP2K2 (Mitogen-activated protein kinase kinase 2) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • WT1 (WT1 Transcription Factor) • ATRX (ATRX Chromatin Remodeler) • BRCA (Breast cancer early onset) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • TSC2 (TSC complex subunit 2) • CHEK2 (Checkpoint kinase 2) • PD-L2 (Programmed Cell Death 1 Ligand 2) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • JAK1 (Janus Kinase 1) • FANCA (FA Complementation Group A) • TSC1 (TSC complex subunit 1) • MDM4 (The mouse double minute 4) • POLD1 (DNA Polymerase Delta 1) • CDK6 (Cyclin-dependent kinase 6) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • AURKA (Aurora kinase A) • JAK3 (Janus Kinase 3) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • CHEK1 (Checkpoint kinase 1) • GATA6 (GATA Binding Protein 6) • MSH3 (MutS Homolog 3) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • GNAS (GNAS Complex Locus) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • CCND2 (Cyclin D2) • CCND3 (Cyclin D3) • CSF1R (Colony stimulating factor 1 receptor) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit) • HDAC1 (Histone Deacetylase 1) • PRDM1 (PR/SET Domain 1) • ZNF217 (Zinc Finger Protein 217) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • GATA3 (GATA binding protein 3) • PARP2 (Poly(ADP-Ribose) Polymerase 2) • PARP3 (Poly(ADP-Ribose) Polymerase Family Member 3) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • ACVR1B (Activin A Receptor Type 1B) • ZNF703 (Zinc Finger Protein 703)

HER-2 mutation • AKT1 mutation

3ms

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial (clinicaltrials.gov)

P2, N=33, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting

3 months ago

Enrollment closed

AKT2 (V-akt murine thymoma viral oncogene homolog 2)

AKT1 mutation

paclitaxel • ipatasertib (RG7440)

3ms

Molecular and histopathological landscape of 131 meningiomas: a retrospective institutional study with insights from cIMPACT-NOW. (PubMed, Front Oncol)

This study provides regional insight into the molecular landscape of meningiomas in our population. While routine molecular profiling adds value to classification and prognostication, broader implementation may be limited by cost and panel coverage constraints.

3 months ago

Retrospective data • Journal

CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • SMO (Smoothened Frizzled Class Receptor) • KLF4 (Kruppel-like factor 4)

CDKN2A deletion • AKT1 mutation

3ms

Understanding biology to identify new therapeutic targets beyond chemotherapy in ovarian granulosa cell tumors (PubMed, Bull Cancer)

For both GCTs subtypes, the CDK4/6-Rb1 axis is promising. Consequently, exploring the molecular features and their role in the biology of these tumors could open up new avenues for targeted and personalized therapies, thereby improving patient care.

3 months ago

Journal • IO biomarker

RB1 (RB Transcriptional Corepressor 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CDK4 (Cyclin-dependent kinase 4) • FOXL2 (Forkhead Box L2)

AKT1 mutation